Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors

Maguire, WF; Schmitz, JC; Scemama, J; Czambel, K; Lin, Y; Green, AG; Wu, SY; Lin, H; Puhalla, S; Rhee, J; Stoller, R; Tawbi, H; Lee, JMJ; Wright, JJ; Beumer, JH; Chu, ED; Appleman, LJ

Appleman, LJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Div Hematol Oncol, Pittsburgh, PA 15213 USA.; Appleman, LJ (corresponding author), UPMC Hillman Canc Ctr, Canc Therapeut Program, 5150 Ctr Ave, Pittsburgh, PA 15232 USA.; Appleman, LJ (corresponding author), Univ Pittsburgh, Sch Med, UPMC Hillman Canc Ctr, Pittsburgh, PA 15232 USA.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021; 88 (4): 643

Abstract

Purpose We investigated the combination of tivantinib, a c-MET tyrosine kinase inhibitor (TKI), and bevacizumab, an anti-VEGF-A antibody. Methods Pati......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索